澳洲生物科技初創企業擔憂新稅務政策將損害創新
Australia's biotech startups fear new tax policies will hurt innovation
Updated at: June 9, 2026 at 02:45 AM
澳洲充滿活力的生物技術產業目前正處於巨大的不確定性中，原因是二〇二六至二〇二七年度聯邦預算案中針對研究與開發稅收優惠（RDTI）所提出的變更。
Australia's vibrant biotechnology sector is currently facing significant uncertainty following proposed changes to the Research and Development Tax Incentive (RDTI) in the 2026-27 Federal Budget.
政府打算將可退還稅收抵免限制在成立不到十年的公司，此舉在整個產業引發了恐慌。
The government intends to limit the refundable tax offset to companies younger than 10 years, a move that has sparked alarm across the industry.
生物技術初創公司在進行臨床試驗和應對監管障礙時，經常處於十多年的虧損狀態——這一階段通常被稱為「死亡之谷」。
Biotech startups frequently operate at a loss for over a decade while navigating clinical trials and regulatory hurdles—a phase often called the 'valley of death.'
在此期間，RDTI的可退還抵免提供了關鍵的現金流，使這些公司得以生存。
During this time, the RDTI's refundable offset provides critical cash flow that allows these firms to survive.
包括AusBiotech在內的產業機構對此提議感到措手不及，並認為這缺乏必要的協商。
Industry bodies, including AusBiotech, were blindsided by this proposal and argue it lacks necessary consultation.
領導者們擔憂，若沒有這項支持，許多本土公司可能會將其臨床計畫和人才轉移到對其更友善的海外司法管轄區。
Leaders fear that without this support, many home-grown companies may move their clinical programs and talent to more supportive overseas jurisdictions.
鑑於該產業支撐了三十五萬個工作職位，且代表著龐大的出口產業，人們日益擔憂這些新的稅收政策，加上資本利得稅可能發生的變更，可能會扼殺創新並阻礙對澳洲健康科技的未來投資。
With the sector supporting 350,000 jobs and representing a massive export industry, concerns are growing that these new tax policies, combined with potential changes to Capital Gains Tax, could stifle innovation and discourage future investment in Australian health technology.
